headbg headbg





Cancer registry based project on survival and care of cancer patients in Europe.



EUROCARE-6 will continue the activity of surveillance and the comparison between survival and care of cancer patients across Europe, initiated with EUROCARE-1,-2,-3, -4, and -5.
The EUROCARE-5 round has documented major survival improvements occurring in the first decade of 2000’s, as a result of advances in cancer management, as well as persistent international differences, especially between Western and Eastern European countries.
Monitoring changes in cancer patients outcome at the population level remains a major goal of the project. Quality and detail of information collected by the European cancer registries has continuously increased over-time. To address evolving and more specific information needs, survival information should be increasingly provided for clinically relevant cancer entities, e.g. by morphological sub-type and by stage at diagnosis. Expanding the availability of clinical variables, particularly those relating to stage at diagnosis and summary treatment, is a priority of the EUROCARE-6 study. This will help to improve the comparability and interpretability of survival analyses results.



The EUROCARE-6 call for data will update the study database by including data of patients diagnosed to 2012 and followed up to 2013 or later, in order to:
·       continue monitoring variations in cancer survival by European country/region, age, time and gender, by including up-to-date data from an increasing number of registries;
·      extend the use of tumour characteristics that potentially influence treatments and outcome, namely: morphology and sub-site localization, stage at diagnosis;
·       study both long-term survival and temporal trends in survival by updating information on life status ascertainment for all cancer patients recorded by cancer registries; for validation and interpretation of survival, incidence may also be analyzed;
·       estimate updated cancer prevalence (complete and by disease duration);
·       estimate updated incidence, survival and prevalence of rare cancers;
·       estimate the proportion of cancer patients who are cured of their disease;
·       estimate the number and proportion of avoidable deaths;